Product · #24 of 27 · multi-symptom
Womaness Me.No.Pause.
Capsule from Womaness, made by Womaness (Well Found, Inc.). Daily serving: 1 capsule.
Last updated · Price and ratings checked Nov 19, 2026
In short: Womaness Me.No.Pause. scores 40.6/100 in our ranking (#24 of 27). It costs $1.57 a day at the regular price. Evidence: Pycnogenol 60 mg (below studied doses), low-dose ashwagandha; best ingredient grade C (Ashwagandha). No NSF registry listing was confirmed.
Pros
- None stood out.
Cons
- No NSF registry listing confirmed.
- Expensive: $1.57 a day at the label dose.
- Evidence: Pycnogenol 60 mg (below studied doses), low-dose ashwagandha.
- Key active is below the dose used in the main studies.
Flags
None found
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Bacognize Bacopa monnieri (whole herb) | 300 mg | Not in our evidence library |
| Ashwagandha root (Withania somnifera) | 100 mg | Ashwagandha C |
| Pycnogenol pine bark extract | 60 mg | Pycnogenol (pine bark) C |
Label photo dated 2021; the product page names the same three actives.
Evidence
Our evidence score: 17/40, because: Pycnogenol 60 mg (below studied doses), low-dose ashwagandha.
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- Ashwagandha C (100 mg here)
Ashwagandha root extract has been studied for occasional stress, sleep quality and common symptoms in perimenopause and menopause* in a few small placebo-controlled trials, all run in India. The Menopause Society 2023: Not assessed. - Pycnogenol (pine bark) C (60 mg here)
Pycnogenol, a French maritime pine bark extract, has been studied in three controlled trials for occasional hot flashes and sleep problems in perimenopause*. The Menopause Society 2023: Not assessed.
Studies
Studies on its ingredients (5)
-
Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study.
100 Indian women in perimenopause took ashwagandha root extract (300 mg twice a day) or placebo for 8 weeks. Menopause symptoms and quality of life improved more with ashwagandha, and hormone levels shifted. The study was short and not yet repeated outside India.
- Who
- 100 perimenopausal women (91 completed)
- Dose
- ashwagandha root extract 300 mg twice daily
- Duration
- 8 weeks
- Result
- Total MRS and MENQoL improved vs placebo; estradiol up, FSH/LH down.
- Funding
- Not stated in abstract; Indian investigators (ingredient-supplier funding typical but not verified). Funding not stated
-
A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Withania somnifera) for managing menopausal symptoms in women.
60 Indian women took ashwagandha root extract or placebo for 8 weeks; symptoms, hot flashes and stress improved more with ashwagandha. Small and short.
- Who
- 60 women aged 45–55
- Dose
- ashwagandha root extract
- Duration
- 56 days
- Result
- MRS, hot-flash events and stress scores improved vs placebo.
- Funding
- Authors declared no conflicts. Independent / academic
-
Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial.
66 Indian postmenopausal women took ashwagandha 600 mg a day or placebo for 12 weeks; sleep and menopause symptoms improved more with ashwagandha.
- Who
- 66 postmenopausal women (63 completed)
- Dose
- ashwagandha root extract 600 mg/day
- Duration
- 12 weeks
- Result
- Better sleep quality (PSQI -5.2 vs -0.8), menopause symptoms and body fat vs placebo; no BMD change.
- Funding
- No conflicts reported. Independent / academic
-
Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial.
170 Japanese women took a low dose of French maritime pine bark extract (60 mg a day) or placebo for 12 weeks. Symptoms, especially hot flashes and sleep, improved more than placebo, though placebo also helped a lot.
- Who
- 170 perimenopausal women (Japan)
- Dose
- Pycnogenol 30 mg twice daily
- Duration
- 12 weeks
- Result
- Kupperman -56% vs -39% placebo (P<.05); hot flashes and sleep improved.
- Funding
- Not stated in abstract (Horphag Research, maker, typically supports Pycnogenol trials; not verified). Funding not stated
-
A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women.
About 200 Taiwanese women took 200 mg pine bark extract or placebo for 6 months, and symptoms improved more with the extract.
- Who
- 200 enrolled, 155 completed (Taiwan)
- Dose
- Pycnogenol 200 mg/day
- Duration
- 6 months
- Result
- All climacteric symptoms improved vs placebo; antioxidant status improved.
- Funding
- Not stated in abstract. Funding not stated
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $46.99 (30 units, 30 days at label dose) |
|---|---|
| Cost per day | $1.57 |
| Subscription | Amazon S&S $42.15 |
| Price notes | BF sale $32.89 (-30%); 90-day 3-pack $140.97; Amazon B096H6M6GM $46.83 |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.3 from 151 ratings on Amazon (checked Nov 19, 2026)
Brand site: ★ 4.9, 52 reviews on womaness.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “vegan” Brand claim
- “gluten-free” Brand claim
- “hormone/phytoestrogen-free” Brand claim
- “non-GMO” Brand claim
- “label tested with 50+ gynecologists/PCPs” Brand claim
Registry check: NSF/ANSI 173 ('Womaness'): not found
Who's behind it
| Brand | Womaness |
|---|---|
| Owner / company | Womaness (Well Found, Inc., St. Paul, MN per label). |
| Founders | Michelle Jacobs & Sally Mueller. |
| Where it's made | Made in USA (Amazon brand claim). Brand claim |
| Medical advisors named |
|
| Source | womaness.com |
Flags & safety
Legal, regulatory and quality flags
No lawsuits, regulator actions or watchdog complaints found in our search for this product or brand.
Ingredient safety notes
- Ashwagandha: Rare liver-injury case reports exist in the literature (not reviewed here); avoid in pregnancy and with thyroid medication — standard cautions (not verified here). Trials reported raised estradiol, lower FSH/LH. Unverified
- Pycnogenol (pine bark): Well tolerated in trials.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.